New study aims to uncover hidden clues in myasthenia gravis

NCT ID NCT07571525

Not yet recruiting Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will follow 40 adults with thymic abnormalities or myasthenia gravis (MG)-related antibodies to better understand how the disease develops and progresses. Researchers will analyze blood, thymus tissue, and muscle samples, along with clinical assessments, to link immune markers with nerve-muscle junction damage. Participants will be monitored for 18 months to track changes over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help identify early signs or predictors of myasthenia gravis, potentially leading to better monitoring or earlier intervention.
What could go wrong: This is an observational study, not a treatment trial. It is small (40 participants) and early-stage, so findings may not apply broadly or lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis thymoma thymus gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS (MG) MYASTHENIA GRAVIS ASSOCIATED WITH THYMOMA THYMOMA

Contacts and locations

Locations

IRCCS Ospedale San Raffaele

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.